<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310401</url>
  </required_header>
  <id_info>
    <org_study_id>3 UO1 HL081332-01S1</org_study_id>
    <nct_id>NCT00310401</nct_id>
  </id_info>
  <brief_title>The Effect of Nebulized Albuterol on Donor Oxygenation</brief_title>
  <official_title>The Effect of Nebulized Albuterol on Donor Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Transplant Donor Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of albuterol versus placebo with the
      following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce
      pulmonary edema, improve donor oxygenation, and increase the number of lungs available for
      transplantation, b) Developing a blood test to predict the development of primary graft
      dysfunction in lung transplant recipients, and c) treating brain dead organ donors with
      albuterol will decrease markers of primary graft dysfunction and lead to improved lung
      transplant recipient outcomes and to higher rates of lungs suitable for transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The donor lung utilization rate in the United States remains less than 15%, and the demand
      for donor lungs far exceeds the available supply. The most common reasons for failure to
      utilize donor lungs are donor hypoxemia and/or pulmonary infiltrates. Since pulmonary edema
      is a common, reversible cause of hypoxemia and infiltrates in patients with brain injury,
      strategies to treat pulmonary edema in organ donors should lead to improved donor
      oxygenation and higher rates of donor lung utilization. Inhaled beta-2 agonists increase the
      rate of alveolar fluid clearance and reduce pulmonary edema in both animal and human lungs.
      In addition, our group has recently reported that the majority of human donor lungs that are
      rejected for transplantation have measurable pulmonary edema and respond to beta-2 agonists
      with increased rates of alveolar fluid clearance. Based on this compelling scientific
      evidence, we propose to test the efficacy of an inhaled beta-2 agonist to increase the rate
      of alveolar fluid clearance and reduce pulmonary edema in brain dead organ donors with the
      following specific aims:

      Specific Aim 1: To test the effect of aerosolized albuterol on donor oxygenation in a
      multicenter, randomized, double-blinded, placebo-controlled trial in 500 brain dead organ
      donors managed over a 2 year period by the California Transplant Donor Network (CTDN).

      Hypothesis 1a: Treatment of brain dead organ donors with aerosolized albuterol will improve
      donor oxygenation and increase the donor lung utilization rate compared to treatment with
      placebo.

      Hypothesis 1b: Treatment of brain dead organ donors with aerosolized albuterol will reduce
      the severity of pulmonary edema in procured lungs compared to treatment with placebo.

      Specific Aim 2: To develop and validate a panel of biological markers that can predict and
      diagnose acute lung injury due to primary graft dysfunction in lung transplant recipients.

      Hypothesis 2a: A panel of plasma biological markers measured in brain dead organ donors that
      includes markers of inflammation, coagulation, endothelial injury and lung epithelial injury
      will predict the development of primary graft dysfunction in the lung recipient.

      Hypothesis 2b: Treatment of brain dead organ donors with inhaled beta-2 agonists will lead
      to reductions in levels of a panel of biological markers of inflammation, coagulation,
      endothelial injury, and lung epithelial injury that will be associated with increased donor
      lung utilization and improved recipient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Donor Oxygenation</measure>
    <time_frame>72 hours or less</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Lung Utilization</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Compliance</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Vascular Resistance</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest X-ray Findings</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">506</enrollment>
  <condition>Brain Death</condition>
  <condition>Organ Donor</condition>
  <condition>Pulmonary Edema</condition>
  <arm_group>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>5 mg nebulized q4h</description>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <other_name>salbutamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brain death

          -  Consent for lung donation and donor research

          -  Release from coroner or medical examiner

        Exclusion Criteria

          -  Age less than 14 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorraine B Ware, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Matthay, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Megan Landeck, RN, BSN, APC</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Transplant Donor Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Transplant Donor Network</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctdn.org</url>
    <description>Organ procurement organization participating in this study.</description>
  </link>
  <reference>
    <citation>Ojo AO, Heinrichs D, Emond JC, McGowan JJ, Guidinger MK, Delmonico FL, Metzger RA. Organ donation and utilization in the USA. Am J Transplant. 2004;4 Suppl 9:27-37.</citation>
    <PMID>15113353</PMID>
  </reference>
  <reference>
    <citation>Rogers FB, Shackford SR, Trevisani GT, Davis JW, Mackersie RC, Hoyt DB. Neurogenic pulmonary edema in fatal and nonfatal head injuries. J Trauma. 1995 Nov;39(5):860-6; discussion 866-8.</citation>
    <PMID>7474001</PMID>
  </reference>
  <reference>
    <citation>Simon RP. Neurogenic pulmonary edema. Neurol Clin. 1993 May;11(2):309-23. Review.</citation>
    <PMID>8316188</PMID>
  </reference>
  <reference>
    <citation>Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev. 2002 Jul;82(3):569-600. Review.</citation>
    <PMID>12087129</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Fang X, Wang Y, Sakuma T, Hall TS, Matthay MA. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung. J Appl Physiol (1985). 2002 Nov;93(5):1869-74.</citation>
    <PMID>12381777</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Wang Y, Fang X, Warnock M, Sakuma T, Hall TS, Matthay M. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet. 2002 Aug 24;360(9333):619-20.</citation>
    <PMID>12241936</PMID>
  </reference>
  <reference>
    <citation>Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant. 2000 Dec;19(12):1199-204.</citation>
    <PMID>11124490</PMID>
  </reference>
  <reference>
    <citation>Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock EP, Cooper JD, Patterson GA. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg. 1995 Jun;109(6):1075-9; discussion 1079-80.</citation>
    <PMID>7776671</PMID>
  </reference>
  <reference>
    <citation>Whiting D, Banerji A, Ross D, Levine M, Shpiner R, Lackey S, Ardehali A. Liberalization of donor criteria in lung transplantation. Am Surg. 2003 Oct;69(10):909-12.</citation>
    <PMID>14570373</PMID>
  </reference>
  <reference>
    <citation>Verghese GM, Ware LB, Matthay BA, Matthay MA. Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. J Appl Physiol (1985). 1999 Oct;87(4):1301-12.</citation>
    <PMID>10517756</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001 May;163(6):1376-83.</citation>
    <PMID>11371404</PMID>
  </reference>
  <reference>
    <citation>Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1250-7.</citation>
    <PMID>2252240</PMID>
  </reference>
  <reference>
    <citation>Ware LB, Golden JA, Finkbeiner WE, Matthay MA. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation. Am J Respir Crit Care Med. 1999 Mar;159(3):980-8.</citation>
    <PMID>10051282</PMID>
  </reference>
  <reference>
    <citation>Campbell AR, Folkesson HG, Berthiaume Y, Gutkowska J, Suzuki S, Matthay MA. Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep. J Appl Physiol (1985). 1999 Jan;86(1):139-51.</citation>
    <PMID>9887124</PMID>
  </reference>
  <reference>
    <citation>Sakuma T, Okaniwa G, Nakada T, Nishimura T, Fujimura S, Matthay MA. Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med. 1994 Aug;150(2):305-10.</citation>
    <PMID>8049807</PMID>
  </reference>
  <reference>
    <citation>Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, Hutter D, Turini P, Hugli O, Cook S, Nicod P, Scherrer U. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002 May 23;346(21):1631-6.</citation>
    <PMID>12023995</PMID>
  </reference>
  <reference>
    <citation>Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med. 2006 Feb 1;173(3):281-7. Epub 2005 Oct 27.</citation>
    <PMID>16254268</PMID>
  </reference>
  <reference>
    <citation>Atabai K, Ware LB, Snider ME, Koch P, Daniel B, Nuckton TJ, Matthay MA. Aerosolized beta(2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med. 2002 Jun;28(6):705-11. Epub 2002 May 17.</citation>
    <PMID>12107675</PMID>
  </reference>
  <reference>
    <citation>de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003 Feb 15;167(4):490-511. Review.</citation>
    <PMID>12588712</PMID>
  </reference>
  <reference>
    <citation>Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation. 2003 Jun 27;75(12):1928-33. Review.</citation>
    <PMID>12829889</PMID>
  </reference>
  <reference>
    <citation>Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, Kimmel SE. Clinical risk factors for primary graft failure following lung transplantation. Chest. 2003 Oct;124(4):1232-41.</citation>
    <PMID>14555551</PMID>
  </reference>
  <reference>
    <citation>Thabut G, Vinatier I, Stern JB, Lesèche G, Loirat P, Fournier M, Mal H. Primary graft failure following lung transplantation: predictive factors of mortality. Chest. 2002 Jun;121(6):1876-82.</citation>
    <PMID>12065352</PMID>
  </reference>
  <reference>
    <citation>Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454-9. Epub 2005 Jun 4.</citation>
    <PMID>16210116</PMID>
  </reference>
  <reference>
    <citation>de Perrot M, Snell GI, Babcock WD, Meyers BF, Patterson G, Hodges TN, Keshavjee S. Strategies to optimize the use of currently available lung donors. J Heart Lung Transplant. 2004 Oct;23(10):1127-34.</citation>
    <PMID>15477105</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2006</firstreceived_date>
  <firstreceived_results_date>June 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Lorraine B. Ware</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>brain death</keyword>
  <keyword>organ donor</keyword>
  <keyword>pulmonary edema</keyword>
  <keyword>albuterol</keyword>
  <keyword>hypoxia</keyword>
  <keyword>lung transplantation</keyword>
  <keyword>infiltrates</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Death</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albuterol</title>
        </group>
        <group group_id="P2">
          <title>Saline</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albuterol</title>
        </group>
        <group group_id="B2">
          <title>Saline</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="260"/>
                <measurement group_id="B2" value="246"/>
                <measurement group_id="B3" value="506"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="224"/>
                <measurement group_id="B2" value="217"/>
                <measurement group_id="B3" value="441"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="43" spread="16"/>
                <measurement group_id="B2" value="42" spread="15"/>
                <measurement group_id="B3" value="42" spread="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="187"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="161"/>
                <measurement group_id="B2" value="158"/>
                <measurement group_id="B3" value="319"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="260"/>
                <measurement group_id="B2" value="246"/>
                <measurement group_id="B3" value="506"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Donor Oxygenation</title>
        <description>The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement</description>
        <time_frame>72 hours or less</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
          </group>
          <group group_id="O2">
            <title>Saline</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="260"/>
                  <measurement group_id="O2" value="246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Donor Oxygenation</title>
            <description>The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement</description>
            <units>cmH2O</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49" lower_limit="-26" upper_limit="149"/>
                  <measurement group_id="O2" value="40" lower_limit="-31" upper_limit="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired T Test was used to compare the change in PaO2/FiO2 ratio from enrollment to procurement between albuterol and saline treated donors</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.98</p_value>
            <method>Paired T Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Lung Utilization</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Compliance</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Vascular Resistance</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chest X-ray Findings</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albuterol</title>
        </group>
        <group group_id="E2">
          <title>Saline</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lorraine B. Ware M.D.</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615 322 8614</phone>
      <email>lorraine.ware@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
